Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Annapolis, MD
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Annapolis, MD
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Santa Fe, NM
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Albany, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Amsterdam, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Amsterdam, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Avon, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Avon, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Batavia, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Batavia, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Bellona, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Bellona, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Canandaigua, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Canandaigua, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Catskill, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Catskill, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Chatham, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Chatham, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Geneva, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Geneva, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Mechanicville, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Mechanicville, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Medina, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Medina, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Palmyra, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Palmyra, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Rochester, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Schenectady, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Schenectady, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Schoharie, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Schoharie, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Troy, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Troy, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Salem, OR
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Salem, OR
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Ashland City, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Ashland City, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Charlotte, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Charlotte, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Franklin, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Gallatin, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Gallatin, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Knoxville, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Lebanon, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Lebanon, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Memphis, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Murfreesboro, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Murfreesboro, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Nashville, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Springfield, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Springfield, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Saint Paul, MN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
Surveillance for Rates of Pertussis Disease Among Persons Birth Through 59 Months of Age Receiving Pentacel® or Other Pertussis Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Madison, WI
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
Surveillance for Rates of Pertussis Disease Among Persons Birth Through 59 Months of Age Receiving Pentacel® or Other Pertussis Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
Surveillance for Rates of Pertussis Disease Among Persons Birth Through 59 Months of Age Receiving Pentacel® or Other Pertussis Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Madison, WI
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
Surveillance for Rates of Pertussis Disease Among Persons Birth Through 59 Months of Age Receiving Pentacel® or Other Pertussis Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Birmingham, AL
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Huntsville, AL
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Downey, CA
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Downey, CA
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
San Diego, CA
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Miami Beach, FL
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Wichita, KA
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Bardstown, KY
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Bardstown, KY
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Nicholasville, KY
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Nicholasville, KY
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Columbia, MD
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Columbia, MD
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Lincoln, NE
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Lincoln, NE
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Lincoln, NE
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Dayton, OH
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Norman, OK
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Norman, OK
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Erie, PA
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Erie, PA
Click here to add this to my saved trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Charleston, SC
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials